Safety and Tolerability of Lenvatinib in Advanced Non-medullary Thyroid Carcinoma: A Multicenter Retrospective Cohort Study From Southwestern Colombia

Background Lenvatinib is standard systemic therapy for radioiodine-refractory differentiated thyroid carcinoma, but real-world safety data from Latin America are limited. We describe the safety and tolerability of lenvatinib in adults with advanced non-medullary thyroid carcinoma treated in southwestern Colombia. Methodology We conducted a retrospective, descriptive, multicenter study of adults with advanced non-medullary thyroid carcinoma treated with lenvatinib at three fourth-level centers in southwestern Colombia. The first documented start was in July 2023, and follow-up was recorded until February 2026. Demographic, oncologic, and safety data were extracted from clinical records. Categorical variables are reported as frequencies with exact 95% confidence intervals (CIs). Continuous variables are reported as median (interquartile range, IQR), except age (mean ± standard deviation, SD). Results Eighteen patients were included; mean age at lenvatinib initiation was 64.4 ± 11.9 years, and n = 10 (55.6%) were women. Histology was papillary in n = 13 (72.2%), poorly differentiated in n = 3 (16.7%), oncocytic follicular in n = 1 (5.6%), and anaplastic in n = 1 (5.6%). The median starting dose was 20 mg/day (IQR 14-23), and n = 13 (72.2%) started below the standard 24 mg. Hypertension was present before treatment in n = 14 (77.8%) and during treatment in n = 16 (88.9%; 95% CI 65.3-98.6). This figure is a prevalence that includes n = 2 (11.1%) new-onset cases and n = 4 (22.2%) with documented worsening or poor control of pre-existing hypertension. Proteinuria was recorded during treatment in n = 11 (61.1%; 95% CI 35.7-82.7), but baseline urinalysis was not documented in any patient, so pre-existing and treatment-emergent proteinuria could not be distinguished. Weight loss (n = 6; 33.3%), diarrhea (n = 5; 27.8%), and asthenia/fatigue (n = 5; 27.8%) were recorded less frequently. Dose reduction was executed in n = 9 (50.0%). Temporary interruption not attributed to administrative causes occurred in n = 5 (27.8%), with an adverse event documented as the reason in one patient. One patient (5.6%) permanently discontinued treatment after a cervical fistula and died. Two further interruptions were administrative (insurer supply failure). Conclusions In this small retrospective cohort, hypertension and proteinuria were the most frequently recorded toxicities, but most of the hypertension burden was pre-existing and proteinuria could not be classified as treatment-emergent. Interpretation is limited by sample size, histologic heterogeneity, missing data, and absence of CTCAE grading.

Authors

Publication Details

Journal
Cureus
Published
2026-11-21
DOI
https://doi.org/10.7759/cureus.120046
Primary Topic
Thyroid Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Safety and Tolerability of Lenvatinib in Advanced Non-medullary Thyroid Carcinoma: A Multicenter Retrospective Cohort Study From Southwestern Colombia

Nathalia Buitrago Gómez, Andrés Felipe García Ramos, Alejandro Román González, Bryan David Zamora et al.
Cureus
Thyroid Cancer Diagnosis and Treatment
article

Safety and Tolerability of Lenvatinib in Advanced Non-medullary Thyroid Carcinoma: A Multicenter Retrospective Cohort Study From Southwestern Colombia

Nathalia Buitrago Gómez, Andrés Felipe García Ramos, Alejandro Román González, Bryan David Zamora, María Alejandra Urbano, Carlos Berrocal, Eduardo José Serna Paz, Alin Abreu Lomba, Andrea Marcela Pantoja Gonzalez, Jhon Herney Quintana Ospina, Marcela Rojas Gil
article en

Abstract

Background Lenvatinib is standard systemic therapy for radioiodine-refractory differentiated thyroid carcinoma, but real-world safety data from Latin America are limited. We describe the safety and tolerability of lenvatinib in adults with advanced non-medullary thyroid carcinoma treated in southwestern Colombia. Methodology We conducted a retrospective, descriptive, multicenter study of adults with advanced non-medullary thyroid carcinoma treated with lenvatinib at three fourth-level centers in southwestern Colombia. The first documented start was in July 2023, and follow-up was recorded until February 2026. Demographic, oncologic, and safety data were extracted from clinical records. Categorical variables are reported as frequencies with exact 95% confidence intervals (CIs). Continuous variables are reported as median (interquartile range, IQR), except age (mean ± standard deviation, SD). Results Eighteen patients were included; mean age at lenvatinib initiation was 64.4 ± 11.9 years, and n = 10 (55.6%) were women. Histology was papillary in n = 13 (72.2%), poorly differentiated in n = 3 (16.7%), oncocytic follicular in n = 1 (5.6%), and anaplastic in n = 1 (5.6%). The median starting dose was 20 mg/day (IQR 14-23), and n = 13 (72.2%) started below the standard 24 mg. Hypertension was present before treatment in n = 14 (77.8%) and during treatment in n = 16 (88.9%; 95% CI 65.3-98.6). This figure is a prevalence that includes n = 2 (11.1%) new-onset cases and n = 4 (22.2%) with documented worsening or poor control of pre-existing hypertension. Proteinuria was recorded during treatment in n = 11 (61.1%; 95% CI 35.7-82.7), but baseline urinalysis was not documented in any patient, so pre-existing and treatment-emergent proteinuria could not be distinguished. Weight loss (n = 6; 33.3%), diarrhea (n = 5; 27.8%), and asthenia/fatigue (n = 5; 27.8%) were recorded less frequently. Dose reduction was executed in n = 9 (50.0%). Temporary interruption not attributed to administrative causes occurred in n = 5 (27.8%), with an adverse event documented as the reason in one patient. One patient (5.6%) permanently discontinued treatment after a cervical fistula and died. Two further interruptions were administrative (insurer supply failure). Conclusions In this small retrospective cohort, hypertension and proteinuria were the most frequently recorded toxicities, but most of the hypertension burden was pre-existing and proteinuria could not be classified as treatment-emergent. Interpretation is limited by sample size, histologic heterogeneity, missing data, and absence of CTCAE grading.

Cureus
Thyroid Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon